Active Biotech’s business strategy is to develop and commercialize proprietary products through strategic partnerships. Active Biotech is currently seeking business partners to secure the continued development of tasquinimod for treatment of multiple myeloma, paquinimod for systemic sclerosis and the pre-clinical SILC project within the oncology field.
Current collaborations include partnerships with NeoTX Therapeutics Ltd. for development of ANYARA in cancer. Active Biotech has since 2004 had an agreement with Teva Pharmaceutical Industries Ltd for development of laquinimod in neurodegenerative and inflammatory diseases. In September 2018, Active Biotech regained the global development and commercialization rights for laquinimod from Teva.
NeoTX Therapeutics Ltd.
On October 26, 2016 – Active Biotech announced an agreement with NeoTX Therapeutics Ltd., for the development and commercialization of Naptumomab estafenatox “ANYARA” for cancer immunotherapy.
The licensing agreement grants NeoTX exclusive rights to develop and commercialize ANYARA worldwide in cancer indications. The total deal value amounts to USD 71 million and is contingent upon achievement of clinical, regulatory and commercial milestones whereof Active Biotech received USD 250,000 as an initial payment upon signing. In addition, NeoTX will pay Active Biotech progressive, double-digit royalties on its net sales.
Teva Pharmaceutical Industries Ltd.
On June 14, 2004 – Active Biotech entered a development and licence agreement with Teva Pharmaceutical Industries Ltd., for develop of laquinimod in neurodegenerative and inflammatory diseases.
The agreement granted Teva exclusive rights to globally develop and commercialize laquinimod. All clinical development of laquinimod was conducted and funded by Teva under this agreement between 2004 and 2018.
On September 5, 2018 – Active Biotech regained the global development and commercialization rights for laquinimod from Teva.